Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$264.32 USD

264.32
312,637

-7.86 (-2.89%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $264.62 +0.30 (0.11%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Here's Why You Should Invest in AmerisourceBergen Right Now

by Zacks Equity Research

AmerisourceBergen's (ABC) consistent pursuit of acquisitions to strengthen core areas buoys optimism.

    Zacks Equity Research

    QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening

    by Zacks Equity Research

    QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.

      Zacks Equity Research

      Cooper Companies Banks on Specialty Lenses, Competition Rife

      by Zacks Equity Research

      Cooper Companies' (COO) flagship silicone hydrogel lenses are expected to see strong sales in the quarters ahead.

        Zacks Equity Research

        Illumina Banks on Product Launches & Strategic Partnerships

        by Zacks Equity Research

        Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.

          Zacks Equity Research

          QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform

          by Zacks Equity Research

          QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.

            Zacks Equity Research

            BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise

            by Zacks Equity Research

            BioScrip's (BIOS) strategic shift toward raising its core revenue mix hampers growth. However, guidance for 2018 buoys optimism on the stock.

              Zacks Equity Research

              GNC Holdings Expands in India, Boosts International Business

              by Zacks Equity Research

              GNC Holdings (GNC) adopts initiatives to increase contributions from international business.

                Zacks Equity Research

                Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                by Zacks Equity Research

                Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.

                  Zacks Equity Research

                  Quest Diagnostics Long-Term View Solid, Reimbursement a Woe

                  by Zacks Equity Research

                  Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.

                    Zacks Equity Research

                    Here's Why You Should Invest in Bio-Rad (BIO) Right Now

                    by Zacks Equity Research

                    Positive tidings on the regulatory front and strong fourth-quarter performance boost investors' confidence in Bio-Rad (BIO).

                      Zacks Equity Research

                      Veeva Systems Vault Clinical Platform to Aid Ora's Operations

                      by Zacks Equity Research

                      Veeva Systems' (VEEV) Vault Clinical Suite to be incorporated into Ora's system for improved patient outcome.

                        Zacks Equity Research

                        Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

                        by Zacks Equity Research

                        Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.

                          Zacks Equity Research

                          Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit

                          by Zacks Equity Research

                          Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.

                            Zacks Equity Research

                            Allscripts (MDRX) Launches Avenel to Revamp EHR Platform

                            by Zacks Equity Research

                            Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.

                              Zacks Equity Research

                              Henry Schien to Distribute Grifols Product in United States

                              by Zacks Equity Research

                              We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

                                Zacks Equity Research

                                Integra LifeSciences Banks on CSS Segment, Competition Rife

                                by Zacks Equity Research

                                Integra LifeSciences (IART) rides high on strength in the Codman Specialty Surgical segment.

                                  Zacks Equity Research

                                  Bio-Rad (BIO) Q4 Earnings Improve Y/Y, Revenues Top Mark

                                  by Zacks Equity Research

                                  Bio-Rad's (BIO) strong sales in Q4 ride high on a robust performance at Life Science product lines.

                                    Zacks Equity Research

                                    Varian (VAR) Rides on Diverse Product Line, Competition Rife

                                    by Zacks Equity Research

                                    Varian Medical (VAR) has a strong international presence and growing proton therapy market. However, intense competition adds to woes.

                                      Zacks Equity Research

                                      Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line

                                      by Zacks Equity Research

                                      Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.

                                        Zacks Equity Research

                                        Medtronic's Guardian Sensor 3 With MiniMed 670G Wins FDA Nod

                                        by Zacks Equity Research

                                        Medtronic (MDT) advances with initiatives to boost the performance of its MiniMed portfolio.

                                          Zacks Equity Research

                                          Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid

                                          by Zacks Equity Research

                                          Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.

                                            Zacks Equity Research

                                            Medtronic (MDT) Expands in the U.S. with 2.0mm DES Launch

                                            by Zacks Equity Research

                                            Medtronic (MDT) consistently focuses on boosting CSH segment.

                                              Zacks Equity Research

                                              PetMed (PET) Focuses on Advertising to Boost New Order Sales

                                              by Zacks Equity Research

                                              PetMed (PETS) implements several strategies to revitalize top line.

                                                Zacks Equity Research

                                                STERIS Focuses on Expanding Core Business, Competition Rife

                                                by Zacks Equity Research

                                                STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.

                                                  Zacks Equity Research

                                                  Will Admissions Drive Universal Health's (UHS) Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Solid performances at Acute Care and Behavioral Health segments are likely to boost Universal Health's (UHS) Q4 results.